AlphAIAlphAI — Financial news for AI agents
intelligencer.caSEP 152 min read$ENVB

Enveric Biosciences Secures New U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series

Enveric Biosciences (ENVB) received a U.S. patent allowance for its EVM401 Series of non-hallucinogenic mescaline-derived compounds, designed to treat PTSD and other psychiatric disorders. This is the third patent in the series, covering novel methylone-inspired compounds. The company aims to strengthen its intellectual property portfolio and develop treatments that promote neuroplasticity without hallucinogenic effects.

Original reporting
intelligencer.ca
Published Sep 15, 2026, 12:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 1:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Enveric Biosciences Secures New U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series — source image
Source · intelligencer.ca
Decision brief

The 30-second read

$ENVBBullishLow
01

Why it matters

The new patent adds composition‑of‑matter protection to the EVM401 series, which could improve the company's competitive moat and attract partnership interest.

02

Market read

A primary corporate disclosure for a small‑cap biotech; modest trading relevance.

03

What to watch

Potential competition from other methylone‑based programs and regulatory timelines.

Relevance 6/10Novelty 7/10Timing: announcement today

Background

Enveric Biosciences (NASDAQ: ENVB) focuses on small‑molecule neuroplastogenic therapeutics for psychiatric disorders.

Company-level read

Ticker impact

$ENVBBullishMedium confidence
Context

Enveric Biosciences received a USPTO Notice of Allowance for a new patent covering its non‑hallucinogenic mescaline‑derived EVM401 series.

Expected impact

Modest upside as investors price in stronger IP protection.

Evidence & confidence

Patents are material for biotech valuations, but the news does not include revenue or clinical data, limiting immediate price impact.

Market effects

Sector

May boost sentiment for the broader neuro‑plasticity biotech niche.

Regional

Limited to U.S. biotech investors; no broader regional effect.

Global

Low global relevance beyond specialty biotech investors.

Counterpoint

What could challenge this read

The patent may not translate into commercial value without clinical success.

Key entities

  • company
    Enveric Biosciences

    Biotech developing neuroplastogenic small‑molecule therapeutics.

  • regulatory_body
    USPTO

    U.S. Patent and Trademark Office granting the allowance.

Read at source← All news

Related articles

AUG 14
$ENVBMed

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026

Enveric Biosciences (NASDAQ: ENVB) reported Q2 2026 results and a corporate update. The company said EB-003 IND-enabling work advanced, including genotoxicity studies, and preclinical assays suggested a non-hallucinogenic and non-photoreactive profile. Enveric also received USPTO patent approvals and raised about $5.0M gross in a private placement plus $1.5M from warrant exercises. Net loss was $3.0M, cash $8.3M.

montrealgazette.com7 min
AUG 14
$ENVBMed

Enveric Biosciences, Inc. (ENVB): Results of Operations and Financial Condition

Enveric Biosciences, Inc. (ENVB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026 EB-003 Development Highlights: ● Continued advancing IND-enabling studies supporting the planned submission of an Investigational New Drug (IND) application for EB-003

SEC EDGAR 8-K6 min
SEP 15
$ASMLLow

TSMC Joins All Four Chipmakers on ASML High-NA EUV; Eindhoven Campus Breaks Ground

ASML has reached a production milestone with 10 High-NA EUV systems operating at TSMC, Samsung, SK Hynix, and Intel, targeting 90% fleet availability by Q4 2026. The company broke ground on a new campus in the Netherlands to meet demand, with plans to produce up to 20,000 workplaces by 2029. TSMC, Samsung, and SK Hynix have committed to High-NA EUV for advanced chip production, while Intel has already processed over 1.35 million wafers. The technology offers higher resolution but comes with incr

techtimes.com3 min
SEP 15
$TTELow

TotalEnergies, Mistral launch AI program for oil and gas exploration

TotalEnergies and Mistral have launched a $115M AI program for oil and gas exploration. The three-year partnership aims to develop AI models for subsurface data analysis, reservoir characterization, and field development. The companies will establish a joint lab to create proprietary tools for TotalEnergies' upstream operations.

worldoil.com2 min
SEP 15
$DRTSHighAI 9/10

Alpha Tau's Cancer Trials Keep Beating Expectations. Three Major Data Readouts Are Next.

Alpha Tau Medical (NASDAQ: DRTS) reported strong results from cancer trials, including a 100% response rate in head and neck cancer and promising data in brain and pancreatic cancers. The company expects key data readouts in late 2026 and early 2027, which could impact its trajectory. Alpha Tau has $104.8 million in cash and a U.S. commercialization partnership with Tolmar.

investegate.co.uk3 min